Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALZN Alzamend Neuro, Inc

Market Closed 12-12 16:00:00 EST

2.17

-0.01

-0.46%

盘后2.17

+0.000.00%

18:35 EST

High2.23	Low2.10	Vol54.66K
Open2.18	D1 Closing2.18	Amplitude5.96%
Mkt Cap8.25M	Tradable Cap8.21M	Total Shares3.80M
T/O119.00K	T/O Rate1.44%	Tradable Shares3.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALZN","market":"US","secType":"STK","nameCN":"Alzamend Neuro, Inc","latestPrice":2.17,"timestamp":1765573200000,"preClose":2.18,"halted":0,"volume":54655,"hourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"18:35 EST","volume":23,"amount":49.71,"timestamp":1765582519091},"delay":0,"floatShares":3784500,"shares":3801600,"eps":-7.148012,"marketStatus":"Market Closed","change":-0.01,"latestTime":"12-12 16:00:00 EST","open":2.18,"high":2.23,"low":2.1,"amount":118998.3365925,"amplitude":0.059633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.148012,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1623729600000,"exchange":"NASDAQ","adjPreClose":2.18,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":2.18,"latestTime":"08:57 EST","volume":106,"amount":227.70000979999998,"timestamp":1765547860579},"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"18:35 EST","volume":23,"amount":49.71,"timestamp":1765582519091},"volumeRatio":1.0411229767185288,"impliedVol":1.3738,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ALZN","defaultTab":"news","newsList":[{"id":"2590327303","title":"Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2590327303","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590327303?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:37","pubTimestamp":1765319864,"startTime":"0","endTime":"0","summary":"Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49294170/alzamend-neuro-q2-eps-0-30-beats-1-96-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2584920227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920227?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:59","pubTimestamp":1763578756,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLAD","RIOT","VVV","NEM","ZION","ALZN","FCX","GOOGL","NNOX","RAPP","DLB","STX","MSTR","DOW","SHBI","GLBE","WDC","NNE","PLUG","RDW","OLMA","GEV","OKLO","CSIQ","TGT","LOW","VTVT","XOM","NVDA","ON","NUVL","OXY","ACHR","SCCO","SION","KZIA","SNDK","COIN","CEVA","DY","CVX","COP","PPL","CDE","ONCY","LZB","PRAX","H","OWL","AGIO"],"gpt_icon":0},{"id":"2584294473","title":"BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study Conducted At Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584294473","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584294473?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:58","pubTimestamp":1763560714,"startTime":"0","endTime":"0","summary":"BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study Conducted At Massachusetts General HospitalAlzamend Neuro Inc ALZN.O:ALZAMEND","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA3SP9BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ALZN"],"gpt_icon":0},{"id":"2584886944","title":"BUZZ-Alzamend rises after completing mid-stage brain lithium study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584886944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584886944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:34","pubTimestamp":1763559274,"startTime":"0","endTime":"0","summary":"BUZZ-Alzamend rises after completing mid-stage brain lithium study** Shares of clinical-stage drug developer Alzamend Neuro ALZN.O rise 5.74% to $2.58 premarket** Co says it finished the clinical portion of a mid-stage trial of AL001, a lithium-based therapy for Alzheimer's and mood disorders** Study compared AL001 with marketed lithium carbonate to measure lithium levels in blood and brain using advanced imaging, co says** Co says goal is to deliver lithium more effectively to the brain while reducing systemic side effects and avoiding frequent blood tests** ALZN expects to release the main results in early 2026** Up to last close, stock down ~77% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALZN","BK4139"],"gpt_icon":0},{"id":"2584949428","title":"Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 \"Lithium in Brain\" Study Conducted at Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949428?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA3SP9BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2584789946","title":"EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2584789946","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584789946?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555400,"startTime":"0","endTime":"0","summary":"Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","BK4139","ALZN"],"gpt_icon":0},{"id":"2584697639","title":"Alzamend Neuro Mourns Loss of Director Andrew Woo","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584697639?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:06","pubTimestamp":1763503614,"startTime":"0","endTime":"0","summary":"Alzamend Neuro ( ($ALZN) ) just unveiled an announcement. Alzamend Neuro, Inc. announced the passing of Andrew H. Woo, M.D., Ph.D., a director who ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-mourns-loss-of-director-andrew-woo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-mourns-loss-of-director-andrew-woo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ALZN","BK4139"],"gpt_icon":0},{"id":"2578540139","title":"Alzamend Neuro Director Lynne Fahey McGrath Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2578540139","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578540139?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:30","pubTimestamp":1761337848,"startTime":"0","endTime":"0","summary":"Lynne Fahey McGrath, Director at Alzamend Neuro Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLbD7CFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2574912581","title":"Alzamend Neuro Inc Issues 361743 Shares of Common Stock Upon Conversion of Series B Preferred","url":"https://stock-news.laohu8.com/highlight/detail?id=2574912581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574912581?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:31","pubTimestamp":1760041870,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc. issued a total of 361,743 shares of common stock between October 1 and October 8, 2025, upon conversion of approximately 839.2 shares of Series B Convertible Preferred Stock. The shares were issued in reliance on an exemption from registration requirements under Section 4 of the Securities Act. The other party to the transaction was holders of the Series B Convertible Preferred Stock. The price per share was not disclosed in the document. As of October 8, 2025, Alzamend Neuro had 3,801,604 shares of common stock outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retriev","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL9K4x6z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ALZN"],"gpt_icon":0},{"id":"2572304861","title":"Director’s Major Stock Sale Shakes Up Alzamend Neuro!","url":"https://stock-news.laohu8.com/highlight/detail?id=2572304861","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572304861?lang=en_us&edition=fundamental","pubTime":"2025-10-01 10:04","pubTimestamp":1759284241,"startTime":"0","endTime":"0","summary":"New insider activity at Alzamend Neuro ( ($ALZN) ) has taken place on September 30, 2025. Director Milton C III Ault has recently sold 79,628 share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/directors-major-stock-sale-shakes-up-alzamend-neuro-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/directors-major-stock-sale-shakes-up-alzamend-neuro-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2572308421","title":"Alzamend Neuro Inc. Director and 10% Owner Milton C. Ault III Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2572308421","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572308421?lang=en_us&edition=fundamental","pubTime":"2025-10-01 07:15","pubTimestamp":1759274154,"startTime":"0","endTime":"0","summary":"Milton C. Ault III, a director and 10% owner, reported a disposal of common shares of Alzamend Neuro Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL3sFwcN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALZN","BK4139"],"gpt_icon":0},{"id":"2570494110","title":"Alzamend Neuro Inc. Issues 300,000 Common Shares Upon Conversion of Series B Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2570494110","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570494110?lang=en_us&edition=fundamental","pubTime":"2025-09-26 04:31","pubTimestamp":1758832297,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc. has issued a total of 300,000 shares of common stock between September 17 and September 25, 2025, following the conversion of 696 shares of Series B Convertible Preferred Stock. The shares were issued privately under an exemption from SEC registration. As of September 25, 2025, the company had 3,439,861 shares of common stock outstanding. The document does not disclose the other party involved or the transaction price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 25, 2025, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL6ccH7z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ALZN"],"gpt_icon":0},{"id":"2570092191","title":"Alzamend Neuro Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2570092191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570092191?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:12","pubTimestamp":1758802320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALZN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 25, 2025 08:12 ET (12:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2570660810","title":"U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust","url":"https://stock-news.laohu8.com/highlight/detail?id=2570660810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570660810?lang=en_us&edition=fundamental","pubTime":"2025-09-25 15:27","pubTimestamp":1758785232,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern TrustSept 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nL3N3VC0H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNRC","SSRM","FLG","ZION","MNPR","CCB","APGE","CMA","EBC","INTC","VLY","MVBF","WAL","NTRS","CUBI","MKC","COLB","WLK","CTAS","ALZN","BDX","WBS","KBH","WOR","BK","BP","HL","PB","ACAD","FHB","HRMY","GH","SSB","STT","EWBC","FHN","ONB","OZK","CBSH","AUB","WSFS","FCX","RNST","WTFC","UMBF","PNFP","CFR","LOB"],"gpt_icon":1},{"id":"2570548950","title":"Alzamend Neuro Inc : Ascendiant Capital Markets Cuts Target Price to $42 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2570548950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570548950?lang=en_us&edition=fundamental","pubTime":"2025-09-25 11:54","pubTimestamp":1758772440,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VB0ZC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","ALZN"],"gpt_icon":0},{"id":"2569746386","title":"Director and 10% Owner Milton C III Ault Reports Disposal of Alzamend Neuro Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2569746386","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569746386?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:31","pubTimestamp":1758659489,"startTime":"0","endTime":"0","summary":"Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDLbTlTG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2567909903","title":"Maxim Group Sticks to Their Hold Rating for Alzamend Neuro (ALZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567909903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567909903?lang=en_us&edition=fundamental","pubTime":"2025-09-13 00:05","pubTimestamp":1757693150,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Hold rating on Alzamend Neuro. The company’s shares opened today a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-alzamend-neuro-alzn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-hold-rating-for-alzamend-neuro-alzn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALZN"],"gpt_icon":0},{"id":"2566987895","title":"Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2566987895","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566987895?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:41","pubTimestamp":1757536917,"startTime":"0","endTime":"0","summary":"Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of $(11.42) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47609579/alzamend-neuro-q1-eps-1-28-misses-0-69-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2566982139","title":"Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2566982139","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566982139?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:31","pubTimestamp":1757536315,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL3M07zn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2565593538","title":"Alzamend Neuro Inc  expected to post a loss of 69 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2565593538","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565593538?lang=en_us&edition=fundamental","pubTime":"2025-09-06 04:16","pubTimestamp":1757103369,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc  expected to post a loss of69cents a share - Earnings Preview Alzamend Neuro Inc ALZN.OQ ALZN.O is expected to  show no change in quarterly revenue when it reports  results on Septe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL8N3US1CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alzamend.com","stockEarnings":[{"period":"1week","weight":-0.0356},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0996},{"period":"6month","weight":-0.3302},{"period":"1year","weight":-0.7974},{"period":"ytd","weight":-0.7921}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.018775},{"month":2,"riseRate":0.25,"avgChangeRate":-0.158027},{"month":3,"riseRate":0.75,"avgChangeRate":0.0205},{"month":4,"riseRate":0.25,"avgChangeRate":-0.118996},{"month":5,"riseRate":0.25,"avgChangeRate":-0.068872},{"month":6,"riseRate":0,"avgChangeRate":-0.237835},{"month":7,"riseRate":0.2,"avgChangeRate":-0.179706},{"month":8,"riseRate":0.4,"avgChangeRate":-0.193815},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01602},{"month":10,"riseRate":0.2,"avgChangeRate":-0.167499},{"month":11,"riseRate":0,"avgChangeRate":-0.126469},{"month":12,"riseRate":0,"avgChangeRate":-0.200444}],"exchange":"NASDAQ","name":"Alzamend Neuro, Inc","nameEN":"Alzamend Neuro, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alzamend Neuro, Inc(ALZN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alzamend Neuro, Inc,ALZN,Alzamend Neuro, Inc股票,Alzamend Neuro, Inc股票老虎,Alzamend Neuro, Inc股票老虎国际,Alzamend Neuro, Inc行情,Alzamend Neuro, Inc股票行情,Alzamend Neuro, Inc股价,Alzamend Neuro, Inc股市,Alzamend Neuro, Inc股票价格,Alzamend Neuro, Inc股票交易,Alzamend Neuro, Inc股票购买,Alzamend Neuro, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alzamend Neuro, Inc(ALZN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction